Abstract
Dopamine transporter (DAT) trafficking was assessed by functional measurements of dopamine uptake and by biotinylation of surface proteins followed by gel electrophoresis and Western blotting. In human embryonic kidney (HEK)-293 cells expressing human DAT (HEK-hDAT), pretreatment with dopamine (0.1-100 μM) followed by washout caused reductions in subsequent dopamine uptake (reflected in Vmax) with effective dopamine concentrations in the 10 to 100 μM range and pretreatment times of 10 to 60 min. Reductions assessed after 60-min pretreatment with 100 μM dopamine corresponded with decreases measured in surface DAT by the noncleavable biotin method, which were caused, at least in part, by enhanced endocytosis as monitored with cleavable biotin. Pretreatment of rat striatal synaptosomes with dopamine (10 and 100 μM) also caused reductions in DAT uptake activity (Vmax), and again the underlying mechanism seemed to be a diminished presence of DAT at the surface of synaptosomes as measured by the noncleavable biotin method. The copresence of cocaine during pretreatment with dopamine prevented the down-regulation of surface DAT. The present results show that DAT surface residency can be regulated by substrate acting on it, not only in cells heterologously expressing DAT but also in situ in rat brain tissue.
Footnotes
-
↵1 Present address: Dept. Psychiatry, Rm. HN 604A, New York University School of Medicine, 556 First Ave., New York, NY 10016.
-
This work was supported by National Institutes of Health Grant DA 11978 (to M.E.A.R.).
-
DOI: 10.1124/jpet.103.055095.
-
ABBREVIATIONS: DAT, dopamine transporter; PKC, protein kinase C; PMA, β-phorbol 12-myristate 13-acetate; GAT1, GABA transporter 1; HEK-hDAT, human embryonic kidney-293 cells expressing human dopamine transporter; PBS/Ca/Mg, phosphate-buffered saline/calcium/magnesium; DA, dopamine; KHR, Krebs-Ringer-HEPES; sulfo-NHS-biotin, sulfosuccinimidobiotin; HA, hemagglutinin; ANOVA, analysis of variance.
- Received May 30, 2003.
- Accepted July 29, 2003.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|